vidofludimus (4sc-101, sc12267) is a novel small molecule inhibitor of dihydroorotate dehydrogenase (dhodh) with an ic50 value of 134nmol/l for human dhodh [1].vidofludimus (4sc-101, sc12267) has been reported to dose-dependently inhibit dhodh in an in vitro enzyme assay with ic50 values of 0.134μmol/l, 1.29μmol/l, 10.6μmol/l and 12.9μmol/l in human dhodh, rat dhodh, mouse dhodh and human pbmc, respectively [1]. in addition, vidofludimus has shown the inhibition of proliferation in phytohemagglutinin-induced lymphocytes with an ic50 value of ~13μmol/l. moreover, vidofludimus has been revealed to concentration-dependently inhibit phytohemagglutinin-stimulated interukin-17 secretion from human peripgeral blppd mononuclear cell lines (pbmcs) with an ic50 value of 6 μmol/l [2].
[1] kulkarni op1, sayyed sg, kantner c, ryu m, schnurr m, sárdy m, leban j, jankowsky r, ammendola a, doblhofer r, anders hj. 4sc-101, a novel small molecule dihydroorotate dehydrogenase inhibitor, suppresses systemic lupus erythematosus in mrl-(fas) lpr mice. am j pathol. 2010 jun;176(6):2840-7.
[2] fitzpatrick lr1, deml l, hofmann c, small js, groeppel m, hamm s, lemstra s, leban j, ammendola a. 4sc-101, a novel immunosuppressive drug, inhibits il-17 and attenuates colitis in two murine models of inflammatory bowel disease. inflamm bowel dis. 2010 oct;16(10):1763-77.
